News | May 02, 2026
Merck posts mixed Q1 2026 results as blockbuster drugs drive growth
But acquisition charges drag earnings into loss
But acquisition charges drag earnings into loss
The twin designations are designed to speed up the development and review of promising medicines targeting serious conditions with high unmet need
Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis
The agreement could rise to $900 million if key commercial milestones are met
The Danish biotech company confirmed the global study will begin in the second half of 2026
EUDRAGIT polymers remain a cornerstone technology in oral drug delivery
The deals, tied to cases in the US District Court for the District of Delaware, effectively extend US patent protection for VYNDAMAX until June 1, 2031
The product is manufactured at AKUMS’ state-of-the-art injectable facility in Kotdwar, Uttarakhand
The move brings one of the country’s most widely prescribed blood thinners onto Cost Plus Drug Company’s online pharmacy platform
The first Phase III and second Phase III trials will be multi-centre, randomised, assessor-blind, active-comparator studies to determine the efficacy, safety and tolerability of orally administered Zintrodiazine
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
